Metabolic research peptides, stocked in Australia
This range gathers the incretin and amylin agonists examined for weight and glucose control (retatrutide, tirzepatide, cagrilintide), the GHRH analogue examined for visceral fat (tesamorelin), and two narrower tools: the hGH fragment AOD-9604 and the exercise-mimetic SLU-PP-332. Each is sold as a research reagent from Australian stock, and retatrutide is additionally kept as a pre-mixed pen.
Retatrutide Pen (70mg)
70mg dual-chamber cartridge pen: lyophilised retatrutide and sterile water, mixed at activation
$729.99
Compounds in this category
AOD-9604
Modified C-terminal fragment of human growth hormone (residues 176-191)
AOD-9604 is a 16-amino-acid piece of human growth hormone, matching residues 176-191 with an extra tyrosine added to the N-terminus. Researchers at Monash University in Melbourne created it to pull the fat-burning stretch of GH away from the regions that drive growth and insulin effects, which makes it one of the rare research peptides to have come out of Australia. Rodent studies reported lower fat mass with no change in food intake.
Cagrilintide
Long-acting amylin analogue
Cagrilintide is a lipidated version of amylin, the hormone the pancreas releases with insulin to signal fullness to the brainstem. Novo Nordisk built it as a once-weekly compound and is testing it both by itself and in a fixed pairing with semaglutide (CagriSema). The Phase 2 dose-ranging trial reported average weight loss of 6.0% to 10.8% at 26 weeks across its doses against 3.0% for placebo, and in REDEFINE-1 the CagriSema combination reported greater reductions than semaglutide alone.
Retatrutide
Triple GLP-1, GIP and glucagon receptor agonist
What sets retatrutide apart is that one synthetic peptide switches on three receptors together, GLP-1, GIP and glucagon, rather than the single target of semaglutide or the two of tirzepatide. Eli Lilly is still running Phase 3 trials on it, which means no licensed medicine exists yet and the only material available is a research vial of the kind shown here. Over 48 weeks the Phase 2 trial recorded average weight reductions of 17.5% at 4mg, 22.8% at 8mg and 24.2% at 12mg weekly, versus 2.1% for placebo, alongside smaller waist circumference and lower blood pressure, triglycerides and liver fat.
SLU-PP-332
Pan-ERR (oestrogen-related receptor) agonist
SLU-PP-332 is a synthetic small molecule that turns on all three oestrogen-related receptors (ERRα, β and γ), the nuclear receptors that drive the gene programs muscle calls up during endurance exercise. Created at Saint Louis University, it is studied as an 'exercise mimetic' in preclinical models. Mice given SLU-PP-332 ran roughly 50-70% longer on treadmill tests and showed more oxidative muscle fibres; obese mice put on less fat while expending more energy.
Tesamorelin
Stabilised growth-hormone-releasing hormone analogue
Tesamorelin is a 44-amino-acid GHRH analogue carrying a trans-3-hexenoic acid group on its N-terminus that shields it from enzymatic breakdown. Its reputation comes from the HIV-associated lipodystrophy trials, in which it cut visceral abdominal fat while avoiding the wider metabolic effects that recombinant growth hormone tends to produce. The Phase 3 trials reported an average 15-18% reduction in visceral adipose tissue on CT at 26 weeks, with triglycerides falling and subcutaneous fat essentially unchanged; visceral fat drifted back toward baseline once the compound was stopped.
Tirzepatide
Dual GIP and GLP-1 receptor agonist
Tirzepatide is a peptide of 39 amino acids that switches on both the GIP and the GLP-1 receptor. As the first dual incretin agonist to finish Phase 3 development, it is now registered as a prescription medicine across many countries. SURMOUNT-1 recorded average weight reductions of 15.0%, 19.5% and 20.9% at 5, 10 and 15mg weekly over 72 weeks (22.5% on the treatment-regimen estimand) against 3.1% for placebo, and the SURPASS trials reported HbA1c reductions near 2 percentage points.
Metabolic Research at a glance
| Compound | Class | Formats | From | Studied for |
|---|---|---|---|---|
| AOD-9604 | Modified C-terminal fragment of human growth hormone (residues 176-191) | 5mg | $99.99 | Adipocyte lipolysis, Lipogenesis inhibition |
| Cagrilintide | Long-acting amylin analogue | 5mg, 10mg | $129.99 | Satiety signalling, Weight regulation |
| Retatrutide | Triple GLP-1, GIP and glucagon receptor agonist | 10mg, 15mg, 20mg, 30mg, 60mg, 15mg pen, 20mg pen, 30mg pen, 70mg pen | $144.99 | Adiposity, Energy expenditure |
| SLU-PP-332 | Pan-ERR (oestrogen-related receptor) agonist | 5mg | $105.99 | Mitochondrial biogenesis, Endurance capacity |
| Tesamorelin | Stabilised growth-hormone-releasing hormone analogue | 5mg, 10mg, 20mg | $89.99 | Visceral adiposity, GH and IGF-1 axis |
| Tirzepatide | Dual GIP and GLP-1 receptor agonist | 20mg, 40mg, 60mg | $249.99 | Glycaemic control, Body composition |
Six compounds, three pathways
Picking between these peptides begins with the pathway each one uses, because the mechanisms are genuinely distinct. Retatrutide and tirzepatide belong to the incretin-receptor class: tirzepatide switches on the GLP-1 and GIP receptors, and retatrutide brings the glucagon receptor in as well. Cagrilintide instead engages the amylin pathway, which signals satiety by way of the brainstem rather than the incretin receptors, so it tends to be studied together with incretin agonists rather than as a replacement for them. Tesamorelin stands on its own as a stabilised growth-hormone-releasing hormone analogue whose Phase 3 work tracked visceral fat by CT instead of body weight. AOD-9604 drives lipolysis in fat cells without touching the growth axis, while SLU-PP-332 is a small-molecule ERR agonist looked at as an exercise mimetic in mice.
Search demand is lopsided toward retatrutide: 'retatrutide australia' pulls roughly fifteen thousand queries a month, trailed by 'retatrutide pen', 'retatrutide price' and 'is retatrutide available in australia'. Most tirzepatide searches point to the registered medicine Mounjaro. Tesamorelin, cagrilintide and AOD-9604 are quieter but steadier research terms.
The reported findings, gathered together
In its Phase 2 obesity trial, retatrutide reported mean weight loss as high as 24.2% at 48 weeks; tirzepatide's SURMOUNT-1 reported up to 22.5% at 72 weeks; cagrilintide on its own reported up to 10.8% at 26 weeks, and more when paired with semaglutide. Tesamorelin's Phase 3 programme reported a 15-18% drop in visceral adipose tissue across 26 weeks with no meaningful change in subcutaneous fat. AOD-9604's human obesity trials fell short of their endpoints, and SLU-PP-332 rests on rodent data alone. Every compound page sets out the study citations, the side effects recorded, and the before-and-after endpoints the trials genuinely measured.
Sizes and formats
Retatrutide is held in five lyophilised vial sizes (10mg to 60mg) and four pre-mixed or dual-chamber pens (15mg to 70mg), with starter kits and value packs that throw in bacteriostatic water and syringes. Tirzepatide is offered in 20mg, 40mg and 60mg vials, tesamorelin in 5mg, 10mg and 20mg, cagrilintide in 5mg and 10mg, AOD-9604 in 5mg and SLU-PP-332 in 5mg. The per-milligram cost drops on the bigger vials; each hub's sizes table shows that figure.
Where things stand legally in Australia
In the research-vial form, none of these metabolic compounds is approved for human use. Tirzepatide does hold a registration as Mounjaro, a prescription pen, and the TGA restricted compounded tirzepatide in 2024; the research vial is a separate product. Retatrutide and cagrilintide remain investigational drugs with no registration anywhere, which means no pharmacy product, no manufacturer's pen and no compounding route. Tesamorelin carries a US registration but not a TGA one. Peptide Aus supplies all of them for in-vitro laboratory research, leaving lawful use to the buyer; the availability and legal guides work through each compound.
Frequently asked questions
Which metabolic peptide draws the most searches in Australia?
Retatrutide, and not closely: roughly 25,000 monthly searches across its cluster, next to about 1,500 for tesamorelin and under 2,000 for tirzepatide research terms.
For research, retatrutide or tirzepatide?
Tirzepatide is the registered, better-characterised dual agonist; retatrutide is the triple agonist with bigger Phase 2 weight loss but no registration. Studies comparing incretin mechanisms frequently run both.
Does tesamorelin count as a weight-loss peptide?
Its trials tracked visceral fat rather than total weight and saw little movement in subcutaneous fat. It is a GHRH analogue, not an incretin agonist.
Can I purchase Mounjaro or Ozempic from you?
No. Both are prescription medicines. Peptide Aus sells research-grade tirzepatide vials for laboratory use and carries no semaglutide.
Is it lawful to have metabolic peptides in Australia?
Supplying them for laboratory research is lawful; in this form none is approved for human use. Every hub carries a legal-status section, and the guides treat retatrutide and tirzepatide at length.
Research use only: every product in this category is intended for in-vitro laboratory research. Not for human or veterinary use.